Thermo Fisher Scientific Inc. $TMO Shares Sold by Heritage Investors Management Corp

Heritage Investors Management Corp reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 56,918 shares of the medical research company’s stock after selling 1,529 shares during the quarter. Thermo Fisher Scientific accounts for 1.1% of Heritage Investors Management Corp’s portfolio, making the stock its 26th largest position. Heritage Investors Management Corp’s holdings in Thermo Fisher Scientific were worth $38,423,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in TMO. BlackRock Inc. bought a new position in shares of Thermo Fisher Scientific in the second quarter worth $15,501,867,000. Corient Private Wealth LP bought a new stake in shares of Thermo Fisher Scientific during the second quarter valued at about $382,547,000. Bank of New York Mellon Corp acquired a new stake in Thermo Fisher Scientific in the second quarter worth about $1,974,561,000. Bank of America Corp DE acquired a new stake in Thermo Fisher Scientific in the second quarter worth about $1,952,930,000. Finally, Legal & General Group Plc acquired a new stake in Thermo Fisher Scientific in the second quarter worth about $1,122,351,000. Institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on TMO. Citigroup raised their target price on shares of Thermo Fisher Scientific from $685.00 to $800.00 and gave the company a “buy” rating in a research note on Friday, October 23rd. DZ Bank lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 23rd. Stifel Nicolaus upped their price target on shares of Thermo Fisher Scientific from $650.00 to $775.00 and gave the stock a “buy” rating in a research note on Thursday, October 22nd. Guggenheim assumed coverage on shares of Thermo Fisher Scientific in a research note on Thursday, October 15th. They set a “buy” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $720.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, September 25th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $689.10.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $696.78 on Monday. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.71. The company’s 50-day moving average price is $654.87 and its two-hundred day moving average price is $552.94. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $711.85. The stock has a market cap of $257.63 billion, a PE ratio of 36.75, a price-to-earnings-growth ratio of 2.84 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, beating the consensus estimate of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The company had revenue of $12.14 billion during the quarter, compared to analyst estimates of $11.95 billion. During the same quarter last year, the firm posted $5.79 EPS. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 25.26 EPS for the current fiscal year.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 275 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $627.05, for a total value of $172,438.75. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at approximately $77,707,171.25. The trade was a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the company’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. This represents a 12.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 76,199 shares of company stock valued at $45,896,780 over the last quarter. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.